| http://www.w3.org/ns/prov#value | - However, sales of the drug collapsed after the introduction of Genentech's Lucentis and rising off-label use of cancer treatment Avastin.Since then, the company has been selling off its products including Visudyne, which was bought by Valeant Pharmaceuticals International Inc. (TSX:VRX), and returning much of the proceeds to shareholders.
|
